Open Access Open Access  Restricted Access Subscription Access

Etiology, Epidemiology, Pathophysiology, Histopathology, Diagnosis, Differential Diagnosis, Treatment and Surgical Oncology of Cervical Cancer

Srinivas G., Ramanjaneyulu D. V., Muralinath E., Guruprasad M., Sravani Pragna K., Manjari P., Sony Sharlet E., T. Nikhil, V. Yaswanth Sai, D. Kusuma Latha, R. Faith Rani, P. Megha Varna, Sahil Manoranjan, M. Malavika Reddy

Abstract


Cervical cancer, the fourth most common cancer among women worldwide, occurred in an entire manner by human papillomavirus (HPV). High-risk types of HPV can result in cervical intraepithelial lesions which, over time, can promote to cervical cancer. In the United States and other developed countries, most screening and early detection efforts involve HPV testing and Papanicolaou (Pap) smears. HPV testing recognizes exposure to both low- as well as high-risk types of HPV, whereas Pap smears recognize abnormal cytology. The majority of cervical cancer cases can be avoided. For cervical cancer, primary prevention and screening are the most efficient ways to lower the disease's mortality and healthcare burden. Since 2006, HPV vaccination has been available to inhibit cervical cancer. Interprofessional team members must educate young female patients (ideally, prior to initiating sexual activity) and their families regarding the highly effectiveness of this vaccine. This activity provides information on current staging, screening recommendations, diagnostic examinations, primary prevention efforts, and particular treatment modalities for invasive cervical cancer.


Full Text:

PDF

References


Brisson, M., & Drolet, M. (2019). Global elimination of cervical cancer as a public health problem. Lancet Oncology, 20(3), 319–321. https://doi.org/10.1016/S1470-2045(19)30014-6

Pimple, S. A., & Mishra, G. A. (2019). Global strategies for cervical cancer prevention and screening. Minerva Ginecologica, 71(4), 313–320. https://doi.org/10.23736/S0026-4784.19.04571-5

Cervical cancer screening every 5 years OK. (2018). Cancer Discovery, 8(10), 1204. https://doi.org/10.1158/2159-8290.CD-18-1013

Farghaly, H., Bourgeois, D., Houser, P. M., Padmanabhan, V., Lage, J. M., & Hoda, R. S. (2006). Routine vaginal Pap test is not useful in women status-post hysterectomy for benign disease. Diagnostic Cytopathology, 34(9), 640–643. https://doi.org/10.1002/dc.20415

Foran, C., & Brennan, A. (2015). Prevention and early detection of cervical cancer in the UK. British Journal of Nursing, 24(10), S22–S29. https://doi.org/10.12968/bjon.2015.24.10.S22

Pierre-Victor, D., Stephens, D. P., Omondi, A., Clarke, R., Jean-Baptiste, N., & Madhivanan, P. (2018). Barriers to HPV vaccination among unvaccinated, Haitian American college women. Health Equity, 2(1), 90–97. https://doi.org/10.1089/heq.2017.0030

Manini, I., & Montomoli, E. (2018). Epidemiology and prevention of Human Papillomavirus. Annali di Igiene: Medicina Preventiva e di Comunità, 30(4 Suppl 1), 28–32. https://doi.org/10.7416/ai.2018.2250

Ghosh, I., Mandal, R., Kundu, P., & Biswas, J. (2016). Association of genital infections other than human papillomavirus with pre-invasive and invasive cervical neoplasia. Journal of Clinical and Diagnostic Research, 10(2), XE01–XE06. https://doi.org/10.7860/JCDR/2016/17973.7243

Habtemariam, L. W., Zewde, E. T., & Simegn, G. L. (2022). Cervix type and cervical cancer classification system using deep learning techniques. Medical Devices (Auckland), 15, 163–176. https://doi.org/10.2147/MDER.S347401

Kuhn, L., & Denny, L. (2017). The time is now to implement HPV testing for primary screening in low resource settings. Preventive Medicine, 98, 42–44. https://doi.org/10.1016/j.ypmed.2016.09.025

Rauh-Hain, J. A., Melamed, A., Schaps, D., Bregar, A. J., Spencer, R., Schorge, J. O., Rice, L. W., & Del Carmen, M. G. (2018). Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies. Gynecologic Oncology, 149(1), 4–11. https://doi.org/10.1016/j.ygyno.2017.12.007

Wang, X., Huang, X., & Zhang, Y. (2018). Involvement of human papillomaviruses in cervical cancer. Frontiers in Microbiology, 9, 2896. https://doi.org/10.3389/fmicb.2018.02896

Romero-Masters, J. C., Lambert, P. F., & Munger, K. (2022). Molecular mechanisms of MmuPV1 E6 and E7 and implications for human disease. Viruses, 14(10). https://doi.org/10.3390/v14102045

Choi, P. W., Liu, T. L., Wong, C. W., Liu, S. K., Lum, Y. L., & Ming, W. K. (2022). The dysregulation of microRNAs in the development of cervical pre-cancer—An update. International Journal of Molecular Sciences, 23(13). https://doi.org/10.3390/ijms23136781

Nowakowski, A., Cybulski, M., Buda, I., Janosz, I., Olszak-Wąsik, K., Bodzek, P., Śliwczyński, A., Teter, Z., Olejek, A., & Baranowski, W. (2016). Cervical cancer histology, staging and survival before and after implementation of organized cervical screening programme in Poland. PLoS One, 11(5), e0155849. https://doi.org/10.1371/journal.pone.0155849

Lax, S. (2011). Histopathology of cervical precursor lesions and cancer. Acta Dermatovenerologica Alpina, Pannonica et Adriatica, 20(3), 125–133.

Jenkins, D. (2007). Histopathology and cytopathology of cervical cancer. Disease Markers, 23(4), 199–212. https://doi.org/10.3233/DMA-2007-23405

Zhang, S., Xu, H., Zhang, L., & Qiao, Y. (2020). Cervical cancer: Epidemiology, risk factors and screening. Chinese Journal of Cancer Research, 32(6), 720–728. https://doi.org/10.21147/j.issn.1000-9604.2020.06.04

Hutchcraft, M. L., & Miller, R. W. (2022). Bleeding from gynecologic malignancies. Obstetrics and Gynecology Clinics of North America, 49(3), 607–622. https://doi.org/10.1016/j.ogc.2022.06.001

Zhdan, V. M., Holovanova, I. A., Vovk, O. Y., & Korosh, M. V. (2021). Relationship between cervical cancer and the level of preventive oncological examinations. Wiadomości Lekarskie, 74(6), 1428–1432.


Refbacks

  • There are currently no refbacks.